Revised SPC: Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), electronic Medicines compendium

Various sections of the SPC have been updated to include information about a third booster dose, including safety and immunogenicity, and to note that the risk of myocarditis after a third dose of the vaccine has not yet been characterised.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news